{"id":"NCT02017717","sponsor":"Bristol-Myers Squibb","briefTitle":"A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients","officialTitle":"A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02-07","primaryCompletion":"2019-06-17","completion":"2024-06-21","firstPosted":"2013-12-23","resultsPosted":"2022-06-29","lastUpdate":"2025-04-04"},"enrollment":529,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Recurrent Glioblastoma"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["BMS-936558"]},{"type":"BIOLOGICAL","name":"Bevacizumab","otherNames":["Avastin"]},{"type":"BIOLOGICAL","name":"Ipilimumab","otherNames":["Yervoy"]}],"arms":[{"label":"Arm N:Nivolumab","type":"EXPERIMENTAL"},{"label":"Arm N + I:Nivolumab + Ipilimumab","type":"EXPERIMENTAL"},{"label":"Arm B: Bevacizumab","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to compare the efficacy and safety of nivolumab administered alone versus bevacizumab in patients diagnosed with recurrent glioblastoma (a type of brain cancer, also known as GBM), and to evaluate the safety and tolerability of nivolumab administered alone or in combination with ipilimumab in patients with different lines of GBM therapy.","primaryOutcome":{"measure":"Percentage of Participants With Drug-Related Adverse Events Leading to Discontinuation by Worst CTC Grade for All Treated Participants in Cohorts 1, 1b, 1c and 1d Who Permanently Discontinued Study Medication Prior to Completing Four Doses","timeFrame":"Includes events reported between first dose and 30 days after last dose of study therapy (up to 3 doses, up to approximately 2 months)","effectByArm":[{"arm":"Cohort 1: Arm N1+I3","deltaMin":0,"sd":null},{"arm":"Cohort 1: Arm N3","deltaMin":0,"sd":null},{"arm":"Cohort 1b: Arm N3+I1","deltaMin":0,"sd":null},{"arm":"Part A Cohort 1c: Arm N3+RT+TMZ","deltaMin":0,"sd":null},{"arm":"Part A Cohort 1d: Arm N3+RT","deltaMin":0,"sd":null},{"arm":"Part B Cohort 1c: Arm N3+RT+TMZ","deltaMin":0,"sd":null},{"arm":"Part B Cohort 1d: Arm N3+RT","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":112,"countries":["United States","Australia","Belgium","Denmark","France","Germany","Italy","Netherlands","Poland","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["39777725","32691060","32437507","30522968"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","http://www.BMSClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":10},"commonTop":["Fatigue","Headache","Nausea","Diarrhoea","Seizure"]}}